SB

Stephanie Van Rumund, BSRT

Senior Clinical Research Associate at Polaris Pharmaceuticals

Stephanie Van Rumund, BSRT has extensive work experience in the field of clinical research. Stephanie most recently served as a Senior Clinical Research Associate at Polaris Pharmaceuticals starting in November 2021. Prior to that, they worked at Toolbox Medical Innovations from December 2019 to November 2021, where they held the position of Senior Clinical Research Associate. Additionally, they worked as a Clinical Research Associate II at Toolbox Medical Innovations from December 2019 to December 2020. Before joining Toolbox Medical Innovations, Stephanie was a Clinical Research Associate (In-House) at Synteract from June 2018 to December 2019. Stephanie also worked as a Clinical Trial Associate II at PPD from May 2016 to May 2018. Stephanie began their career at Best Buy, where they served as a Project Team Supervisor from September 2015 to May 2016 and as a Project Team Merchandiser from August 2009 to September 2015.

Stephanie Van Rumund, BSRT, earned a Bachelor of Science (BS) degree in Respiratory Care Therapy/Therapist from Independence University, where they studied from 2015 to 2017. Prior to that, they obtained an Associate of Science degree in Respiratory Care Therapy/Therapist from California College San Diego, where they studied from 2013 to 2015.

In addition to their degrees, Stephanie has obtained several certifications. In July 2015, they became a Registered Respiratory Therapist through the National Board for Respiratory Care (NBRC). In April 2015, they also earned the certification of Certified Respiratory Therapist, also from the NBRC. Furthermore, in November 2017, Stephanie became a Respiratory Care Practitioner through the Respiratory Care Board of California.

Location

San Diego, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Polaris Pharmaceuticals

Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans. Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma. Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia. Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.